Immuneering Announces Pricing of Upsized Initial Public Offering

NEXT STORY
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
PREV STORY
Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Philips showcases integrated radiation oncology portfolio to provide a confident path to treatment at ASTRO 2019

author_avatar
NASDAQ Market News

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

author_avatar
NASDAQ Market News

Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE

author_avatar
NASDAQ Market News